Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline


New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists

Saint-Prex, Switzerland, 25 November 2014 –New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for degarelix (FIRMAGON®), a gonadotropin releasing hormone (GnRH) antagonist, compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists. In addition, the data showed a reduction in the incidence of joint, musculoskeletal and urinary tract adverse events for those men with prostate cancer treated with degarelix rather than LHRH agonists. However, the overall rate of any adverse event (including hot flush and injection-site reactions) was higher in the degarelix group than the LHRH agonist group.

Click here to read more

See more Newsroom


Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692